Current Report Filing (8-k)
April 12 2023 - 7:35AM
Edgar (US Regulatory)
0001860742
false
Bausch & Lomb Corp
0001860742
2023-04-10
2023-04-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
April 10, 2023
Date of Report (Date of the earliest event
reported)
Bausch + Lomb Corporation
(Exact Name of Registrant as Specified
in Its Charter)
|
|
|
|
|
Canada |
|
001-41380 |
|
98-1613662 |
(State
or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
520 Applewood Crescent
Vaughan, Ontario
Canada L4K 4B4
(Address of Principal Executive Offices)(Zip
Code)
(905) 695-7700
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Shares |
|
BLCO |
|
New York Stock Exchange, Toronto Stock Exchange |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On April 12, 2023, Bausch + Lomb Corporation
(the “Company”) announced the upcoming departure of Christina M. Ackermann as Executive Vice President & General Counsel
and President, Ophthalmic Pharmaceuticals of the Company. This change was approved on April 10, 2023 and will become effective as of April
24, 2023, and Ms. Ackermann’s employment with the Company will end, effective as of April 28, 2023.
In connection with Ms. Ackermann’s
departure, on April 12, 2023, the Company announced that, effective as of April 24, 2023, A. Robert D. Bailey will be appointed as the
Company’s Executive Vice President & Chief Legal Officer, and Andrew Stewart will be appointed as the Company’s President,
Ophthalmic Pharmaceuticals.
Mr. Bailey has over 25 years of
experience as a senior executive and more than 15 years as a chief legal officer at private and publicly traded companies in the
health care industry, including formerly serving as EVP, Law, Policy and Communications at Bausch + Lomb from 2007 to 2013. He will
rejoin Bausch + Lomb from Datavant, a private health information technology company, where he
has most recently served as Chief Legal Officer. Previously, he served as EVP,
Chief Legal Officer and Corporate Secretary of Allergan plc and its predecessor companies, Forest Laboratories Inc. and Actavis
plc.
Mr. Stewart has
more than 25 years of experience in the pharmaceutical industry. He will join Bausch + Lomb from AbbVie, where he has most recently served
as general manager within the Eye Care franchise. At AbbVie and its predecessor company, Allergan plc, Mr. Stewart also previously had
responsibility for the U.S. Retina business, led global marketing for the Eye Care franchise and oversaw business development initiatives
for the Eye Care franchise.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
Signatures
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
BAUSCH + LOMB CORPORATION |
|
|
|
|
By: |
|
/s/ Brenton L. Saunders |
|
Name: |
|
Brenton L. Saunders |
|
Title: |
|
Chairman and Chief Executive Officer |
|
Date: April 12,
2023
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Jul 2023 to Jul 2024